US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 2.190
- -0.350-13.78%
Close Nov 22 16:00 ET
- 2.310
- +0.120+5.48%
Post 20:02 ET
3.43MMarket Cap0.29P/E (TTM)
2.650High2.000Low114.03KVolume2.480Open2.540Pre Close263.60KTurnover8.54%Turnover RatioLossP/E (Static)1.57MShares23.20052wk High0.12P/B2.92MFloat Cap2.00052wk Low--Dividend TTM1.34MShs Float1390.000Historical High--Div YieldTTM25.59%Amplitude2.000Historical Low2.311Avg Price1Lot Size
Purple Biotech Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 9.87%-3.3M | 23.88%-3.98M | 16.19%-5.08M | -19.06%-19.93M | -18.22%-4.98M | -0.97%-3.66M | -41.16%-5.22M | -16.62%-6.06M | -12.49%-16.74M | -18.94%-4.21M |
| Net income from continuing operations | 86.79%-668K | 53.20%-2.42M | 22.88%-3.78M | 8.19%-19.98M | 19.59%-4.86M | -4.25%-5.06M | -45.27%-5.16M | 32.98%-4.9M | -22.07%-21.76M | -27.17%-6.04M |
| Depreciation and amortization | -2.00%49K | -7.55%49K | 4.35%48K | -1.99%197K | -4.00%48K | 6.38%50K | 0.00%53K | -9.80%46K | -12.99%201K | -18.03%50K |
| Other non cash items | -111.71%-1.47M | -4,000.00%-975K | -212.79%-685K | -172.12%-2.29M | -152.33%-1.41M | -198.28%-692K | 165.79%25K | -1,360.00%-219K | -680.56%-843K | -4,392.31%-558K |
| Change In working capital | -184.36%-1.34M | -66.40%-1.06M | 46.55%-930K | -91.58%274K | -29.51%1.06M | 125.50%1.59M | 11.94%-634K | -198.25%-1.74M | 337.50%3.26M | 80.48%1.5M |
| -Change in payables and accrued expense | -218.17%-1.48M | -30.89%-1.11M | 42.64%-717K | -91.20%258K | 21.73%1.1M | 81.36%1.26M | 46.11%-845K | -143.03%-1.25M | 183.74%2.93M | -2.38%902K |
| -Change in other current assets | -58.46%140K | -75.83%51K | 35.26%-213K | -43.13%178K | -109.38%-41K | 108.02%337K | -75.12%211K | 70.99%-329K | 199.05%313K | 461.16%437K |
| -Change in other working capital | ---- | ---- | ---- | -1,572.73%-162K | -100.63%-1K | --0 | --0 | ---161K | -59.26%11K | --159K |
| Cash from discontinued investing activities | 0 | 0 | ||||||||
| Operating cash flow | 9.87%-3.3M | 23.88%-3.98M | 16.19%-5.08M | -19.06%-19.93M | -18.22%-4.98M | -0.97%-3.66M | -41.16%-5.22M | -16.62%-6.06M | -9.73%-16.74M | -12.28%-4.21M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -92.84%72K | -56.06%87K | -97.52%312K | -30.30%13.88M | -99.07%74K | 468.36%1.01M | 103.31%198K | -28.86%12.6M | 48.55%19.91M | 58.11%8M |
| Net PPE purchase and sale | --0 | --0 | --0 | 88.46%-3K | --0 | 116.67%1K | 83.33%-1K | 78.57%-3K | 77.39%-26K | --0 |
| Net intangibles purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---202K | --0 |
| Net business purchase and sale | --0 | --0 | --0 | ---3.55M | --0 | --0 | --0 | ---3.55M | --0 | --0 |
| Net investment purchase and sale | -100.34%-3K | 66.67%5K | -98.82%187K | -15.84%16.68M | -100.08%-6K | 87,700.00%878K | 100.05%3K | -11.22%15.8M | 50.57%19.82M | 60.08%8M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -92.84%72K | -56.06%87K | -97.52%312K | -30.30%13.88M | -99.07%74K | 468.36%1.01M | 103.31%198K | -28.86%12.6M | 48.55%19.91M | 58.11%8M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 273.08%2.13M | 17.98%433K | 1.52%268K | 389.14%5.45M | 4,670.79%4.25M | 0.53%572K | 24.83%367K | 62.96%264K | -26.32%1.11M | -81.42%89K |
| Net issuance payments of debt | -4.76%-44K | -9.52%-46K | -7.14%-45K | -1.82%-168K | -2.44%-42K | -2.44%-42K | -2.44%-42K | 0.00%-42K | -7.84%-165K | 0.00%-41K |
| Net common stock issuance | -25.66%504K | 16.05%564K | -5.32%374K | 4.34%1.56M | -97.85%4K | 2.88%678K | 14.89%486K | 71.74%395K | 165.60%1.5M | -67.02%186K |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --5M | --5M | ---- | ---- | ---- | --0 | ---- |
| Net other financing activities | -572.55%-343K | -20.97%-75K | 33.33%-50K | -485.53%-890K | -1,747.37%-702K | -54.55%-51K | 13.89%-62K | -733.33%-75K | -533.33%-152K | -65.22%-38K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 273.08%2.13M | 17.98%433K | 1.52%268K | 389.14%5.45M | 4,670.79%4.25M | 0.53%572K | 24.83%367K | 62.96%264K | -26.32%1.11M | -81.42%89K |
| Net cash flow | ||||||||||
| Beginning cash position | -62.07%6.52M | -54.37%9.99M | -3.60%14.49M | 38.02%15.03M | 36.39%15.1M | 22.82%17.2M | -7.03%21.88M | 38.02%15.03M | -3.17%10.89M | 21.47%11.07M |
| Current changes in cash | 47.59%-1.09M | 25.81%-3.46M | -166.18%-4.5M | -113.86%-595K | -117.09%-662K | 27.72%-2.08M | 50.36%-4.66M | -46.34%6.8M | 1,389.19%4.29M | 117.03%3.87M |
| Effect of exchange rate changes | 115.00%3K | 78.26%-5K | -104.00%-2K | 135.29%54K | -42.68%47K | 64.91%-20K | 84.35%-23K | 261.29%50K | -537.50%-153K | 783.33%82K |
| End cash Position | -64.00%5.44M | -62.07%6.52M | -54.37%9.99M | -3.60%14.49M | -3.60%14.49M | 36.39%15.1M | 22.82%17.2M | -7.03%21.88M | 38.02%15.03M | 38.02%15.03M |
| Free cash flow | 9.85%-3.3M | 23.89%-3.98M | 16.24%-5.08M | -17.48%-19.93M | -18.22%-4.98M | -0.80%-3.66M | -40.96%-5.22M | -12.00%-6.07M | -10.39%-16.96M | -12.28%-4.21M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data